Mumbai, May 14 (Udaipur Kiran): Indoco Remedies is currently trading at Rs. 227.75, up by 1.75 points or 0.77% from its previous closing of Rs. 226.00 on the BSE.
The scrip opened at Rs. 225.30 and has touched a high and low of Rs. 234.05 and Rs. 223.50 respectively. So far 7190 shares were traded on the counter.
The BSE group ‘B’ stock of face value Rs. 2 has touched a 52 week high of Rs. 348.10 on 17-Jul-2025 and a 52 week low of Rs. 163.70 on 30-Mar-2026.
Last one week high and low of the scrip stood at Rs. 270.00 and Rs. 196.10 respectively. The current market cap of the company is Rs. 2084.68 crore.
The promoters holding in the company stood at 58.86%, while Institutions and Non-Institutions held 19.09% and 22.04% respectively.
Indoco Remedies has successfully cleared Malta Medicines Authority audit. The Malta Medicines Authority had inspected the company’s manufacturing facility for solid oral dosage form (Unit I) located at Baddi from January 29, 2026, to February 3, 2026. The facility has received EU GMP certification from the Malta Medicines Authority confirming that it complies with the Good Manufacturing Practice requirements as referred in the EC Directive.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.